The fast pace of innovation in biotech is the biggest risk to Illumina's future. With a $42 billion market...
This tech company is quietly transforming into an innovator once again, delivering growing income that isn't showing any signs of stopping.
Former floor trader Alan Knuckman provides details on his new trading strategy.
All three of these bargains have forward P/E ratios of less than eight.
They may not be leading the market right now, but if history is any guide, then value stocks are poised to outperform. Here's why...
Just as U.S. stocks have run into higher volatility and major drawdowns in recent months, EM stocks have also encountered head winds.
A few surprising aspects about the $1.2 trillion market for food on the go.
There's no limit to where and how far this $2 billion company can go -- it's a $100 billion industry leading blue-chip in the making.
We've made three short-term income trades with this stock in the last six months, and each one has been a winner. And we're five-for-five on trades since I first started using this strategy. Let's add another win (and some more income) to our record...
A recession is coming, the Fed is unprepared and it’s extremely unlikely the Fed will be prepared in time.
Which cloud-based healthcare technology stock wins in a head-to-head matchup?